



HIV Pre-exposure Prophylaxis

Challenges of clinical trial design, degree of evidence and recommendations in the era of PrEP

9.00 Registration

9.30 – 9.45 Welcome address

Dr. Constance Delaugerre, Hôpital Saint-Louis & Sidaction, France

9.45 What we know, what we are learning, and what more we need to do

Mr. Mitchell Warren, AVAC, USA

Where are we now? A review of recent results, current trials and planned trials

Prof. Robert Grant, MD, Gladstone Institute of Virology and Immunology, USA

PrEP Update: From intentions to use (Understanding safety, efficacy, correlates of protection, surrogate markers and trends in sexual behaviour)

11h15 Recommendations' production

Dr. Kevin O'Reilly, WHO, Switzerland

Moving from research to implementation: What we still need to know

Dr. Roger Tatoud, Imperial College, Great Britain

PrEP in the UK: From research to policy and back

12.45 Lunch

14.00 Ongoing researches: objectives, designs, levels of evidence and ethical issues

Mr. Georges Sideris, The Warning, France

Mr. Hugues Fischer, Act Up-Paris, France

Mr. Jean-Marie Le Gall, Aides, France

Community-based organizations points of view on ethical issues

Prof. Benoît Mâsse, University of Montreal, Canada

Evaluating interventions without placebo controls

16.00 Round table

Chair: Mr. Christophe Martet, Yagg, France

Mr. Antonio Alexandre, SNEG, France

Prof. Jean-François Delfraissy, MD, ANRS, France

Mr. Stephen Karon, Ipergay's Community Advisory Board, France

Prof. Jean-Michel Molina, MD, Hôpital Saint-Louis, France

Prof. Willy Rozenbaum, MD, Hôpital Saint-Louis, France

Dr. Bruno Spire, Aides, France

17.30 Concluding remarks

Mr. Vincent Douris and Mrs. Veronica Nosedá, Sidaction, France

January 29, 2013 – Mairie du 10^e arrondissement

72, rue Fbg. Saint-Martin, 75010 Paris – Metro station Château d'Eau, Line 4